Long-term dosage effects of psychodynamic and schema therapy in depressed patients with personality disorders: 18 and 24 months follow-up of a randomized controlled trial
Psychological Medicine · 2025
DOI: 10.1017/s0033291725101025 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Psychological Medicine, 2025. Verfasst von Marit Kool und 5 weiteren Autor:innen. Beteiligte Einrichtung: Research Department, Arkin Foundation: Stichting Arkin, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Personality Disorders, Psychotherapy, Psychodynamic, Psychotherapy, Depressive Disorder. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Providing psychotherapy at 50 sessions in a year (starting twice weekly) led to faster and greater improvements in depression and personality functioning compared to 25 sessions, starting weekly for patients with depression and personality disorder (PD). This study reports long-term dosage effects at 18 and 24 months.
Methods
In a pragmatic, double-randomized clinical trial, 246 outpatients with depression and PD were assigned to (1) 25 or 50 sessions and (2) Short-term Psychodynamic Supportive Psychotherapy (SPSP) or Schema Therapy (ST). Depression severity was assessed with the Beck Depression Inventory-II. Secondary outcomes included diagnostic remission of depression (MINI-plus), PD (SCID-II/SCID-5-P), and treatment-specific measures. Intention-to-treat analyses were conducted.
Results
At 18 and 24 months, BDI-II means did not differ between dosage groups (19.0 for 25 sessions versus 19.1 for 50 sessions; d = −0.01; 95% CI = −0.35-0.37, p = 0.96). The lower-dosage group improved during follow-up (−2.6 BDI points, p = 0.031), which may be partly attributed to additional therapy received by a subgroup. Remission rates at 24 months were 66% for depression and 76% for PD, with no differences between conditions.
Conclusions
Higher psychotherapy dosage led to faster initial improvements, but long-term outcomes were not superior to those achieved with a lower dosage. These results should be interpreted with caution, as unregulated treatment during follow-up reduced the power to detect significant dosage effects. Both SPSP and ST provide viable alternatives to treatments focused solely on depression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Department, Arkin Foundation: Stichting Arkin, Amsterdam, The Netherlands.
- Department of Clinical Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Department of Psychology, University of Amsterdam, The Netherlands.
ORCID-Profile: Marit Kool
Zitieren
APA
Kool, M., van den Eshof, V. H., Van, R., Dekker, J., Peen, J., & Arntz, A. (2025). Long-term dosage effects of psychodynamic and schema therapy in depressed patients with personality disorders: 18 and 24 months follow-up of a randomized controlled trial. Psychological Medicine. https://doi.org/10.1017/s0033291725101025
Vancouver
Kool M, van den Eshof VH, Van R, Dekker J, Peen J, Arntz A. Long-term dosage effects of psychodynamic and schema therapy in depressed patients with personality disorders: 18 and 24 months follow-up of a randomized controlled trial. Psychological Medicine. 2025. doi:10.1017/s0033291725101025
BibTeX
@article{Kool2025,
author = {Kool, Marit and van den Eshof, Voor Hannah and Van, Rien and Dekker, Jack and Peen, Jaap and Arntz, Arnoud},
title = {Long-term dosage effects of psychodynamic and schema therapy in depressed patients with personality disorders: 18 and 24 months follow-up of a randomized controlled trial},
journal = {Psychological Medicine},
year = {2025},
doi = {10.1017/s0033291725101025}
}
EUVIMED